Snubbed Novo deputy: “It was a choice. I became a part of Lars’ plan”
A reshuffle at the top in Novo Nordisk has left Jakob Riis in charge of the drug group’s US business – and not the CEO position that he had been seen as a candidate for. If that makes him search out greener pastures, Novo’s rivals will be lining up to welcome him, a number of headhunters believe.
BY ERIK HOLM, SILLE WULFF MORTENSEN, BENJAMIN WERNER CHRISTENSEN & STEFAN SINGH KAILAY
Jakob Riis was weeks away from celebrating his 20 year anniversary in Novo Nordisk when he received what is likely to have been the biggest disappointment of his career.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
